Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500091 | 0.93 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL1488560 | 0.89 | MAP2K1 (0.60) | MAP2K1MAP2K2KDM4E | |
| SCHEMBL3973762 | 0.89 | NUDT1 (0.42) | MAP2K1MAP2K2KDM4E | |
| SCHEMBL29413590 | 0.89 | MAP2K1 (0.60) | MAP2K1MAP2K2KDM4E | |
| SCHEMBL3978440 | 0.89 | CLCN2 (0.42) | MAP2K1MAP2K2KDM4E | |
| SCHEMBL1342912 | 0.89 | MAP2K1 (0.40) | MAP2K1MAP2K2KDM4E | |
| SCHEMBL4239049 | 0.89 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL3972045 | 0.89 | MAP2K1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL3980231 | 0.88 | MAP2K1 (0.56) | MAP2K1MAP2K2FPR2KDM4E | |
| SCHEMBL1488337 | 0.88 | MAP2K1 (0.53) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | claimed |
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1673339-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7271178-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2007022529-A2 | METHOD OF TREATING INFLAMMATORY DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7144907-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1673339-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 94/4885MAP2K2 85/4885FPR2 1870/4885 |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 92/4885MAP2K2 85/4885FPR2 1763/4885 |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 92/4885MAP2K2 88/4885FPR2 1808/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | MAP2K1 92/4885MAP2K2 85/4885FPR2 1763/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | MAP2K1 4674/4885MAP2K2 4515/4885FPR2 89/4885 |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | NRAS, BRAF, RAF1 | MAP2K1 42/4885MAP2K2 38/4885FPR2 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.